Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide.
The Worldwide Market for Rheumatoid Arthritis and Lupus Treatments report is the most comprehensive look at the markets for treatments for these two important diseases. As part of its thorough, ground up research-- the product of interviews with market experts conducted by an experienced pharmaceutical market analyst, this report includes:
Market Size and Forecast for NSAIDs and Biologic Treatments
New Products in Development
Important Issues and Trends
Company Profiles
Market Share
Regional Revenues Breakout
Product Managers, marketing managers, business development executives and investment professionals are among those who will find this report to be a useful resource.
Table of Contents
TABLE OF CONTENTS
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Size and Growth of the Market
Leading Competitors
CHAPTER TWO: INTRODUCTION
History of the Market
Immune System
Autoimmunity
Genetic Factors
Environmental Factors
Gene Research
Distribution
Technology
Demographics
CHAPTER THREE: MARKETS FOR RHEUMATOID ARTHRITIS
Overview
Description of Rheumatoid Arthritis
Diagnosis
Treatment Guidelines
Economic Impact of Disease
Trends in Insurance and Reimbursement
Description of products
Non-steroid Anti-inflammatory Drugs
Biologic Treatments
Disease Modifying Anti-rheumatic Drugs (DMARDs)
Immunosuppressant and Other Biologic Drugs
New Developments
Market Overview
Market by Product Type
Market by Geographical Region
Competitive Analysis
Corporate Profiles
Abbott Laboratories
Amgen, Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb
Centocor, Inc.
Genentech, Inc.
Merck & Company, Inc.
Novartis International AG
Pfizer, Inc.
Schering-Plough Corporation
Wyeth
CHAPTER FOUR: MARKETS FOR LUPUS ERYTHEMATOSUS
Overview
Description of Lupus Erythematosus
Diagnosis
Risk Factors
Treatment Guidelines
Economic Impact of Disease
Trends in Insurance and Reimbursement
Description of products
New Developments
Market Overview
Market by Product Type
Market by Geographical Region
Competitive Analysis
Corporate Profiles
Aspreva Pharmaceuticals Corporation
Bristol-Myers Squibb
Genelabs Technologies, Inc.
Genentech, Inc.
GlaxoSmithKline plc
Human Genome Sciences
La Jolla Pharmaceutical Company
Roche
UCB S.A.
CHAPTER FIVE: TOTAL MARKET SIZE AND FORECAST
Overview
Total Market Size and Forecast
Markets by Segments
Leading Competitors
CHAPTER SIX: LIST OF COMPANIES
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: The World Market for Prescription Rheumatoid Arthritis
and Lupus Treatments, 2004-2011
Figure 1-1: The World Market for Prescription Rheumatoid Arthritis
and Lupus Treatments, 2004-2011
CHAPTER TWO: INTRODUCTION
Table 2-1: World Population by Selected Geographical Region, 2006-2050
Figure 2-1: World Population by Selected Geographical Region, 2006-2050
Table 2-2: Estimated World Population by Age and Geographical Region, 2006
Table 2-2: Estimated World Population by Age and Geographical Region, 2006
CHAPTER THREE: RHEUMATOID ARTHRITIS MARKETS
Table 3-1: World Prevalence of Rheumatoid Arthritis by Region25
Figure 3-1: World Prevalence of Rheumatoid Arthritis, Percent by Region
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.
